Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 34.35
-0.60 (-1.72%)
Aug 19, 2026, 11:04 AM CST
Medigen Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,269 | 1,583 | 1,373 | 1,158 | 1,056 | 3,922 | |
Revenue Growth | -22.05% | 15.28% | 18.57% | 9.64% | -73.08% | 537.16% |
Cost of Revenue | 611.42 | 677.48 | 618.94 | 540.39 | 968.49 | 1,371 |
Gross Profit | 657.17 | 905.02 | 753.76 | 617.33 | 87.46 | 2,551 |
Selling, General & Admin | 552.07 | 558.15 | 571.21 | 499.64 | 402.31 | 376.61 |
Research & Development | 349.54 | 451.9 | 393.27 | 1,336 | 1,331 | 1,407 |
Other Operating Expenses | -5.11 | 47.3 | - | - | - | -1.36 |
Operating Expenses | 900.85 | 1,062 | 970.95 | 1,850 | 1,754 | 1,771 |
Operating Income | -243.68 | -156.99 | -217.2 | -1,233 | -1,667 | 779.96 |
Interest Expense | -27.44 | -23.12 | -36.39 | -55.86 | -39.45 | -19.07 |
Interest & Investment Income | 32.76 | 35.26 | 52.4 | 89.07 | 8.88 | 3.16 |
Earnings From Equity Investments | -61.64 | -43.08 | -28.44 | -92.26 | -262.21 | -98.8 |
Currency Exchange Gain (Loss) | -30.71 | -30.71 | 43.22 | -0.13 | 29.49 | 3.39 |
Other Non Operating Income (Expenses) | 52.2 | 8.57 | 5.24 | 24.03 | 74.31 | 457.12 |
EBT Excluding Unusual Items | -278.5 | -210.08 | -181.17 | -1,268 | -1,856 | 1,126 |
Gain (Loss) on Sale of Investments | 0.04 | 0.04 | -1.52 | -9.58 | -16.66 | 10.92 |
Gain (Loss) on Sale of Assets | -9.06 | -9.06 | 69.27 | -1.03 | - | -0.25 |
Other Unusual Items | 0.5 | 0.5 | 0.7 | - | 0 | - |
Pretax Income | -287.02 | -218.6 | -112.72 | -1,279 | -1,873 | 1,136 |
Income Tax Expense | 73.84 | 77.35 | 109.67 | 191.21 | 58.87 | 65.73 |
Earnings From Continuing Operations | -360.86 | -295.95 | -222.39 | -1,470 | -1,931 | 1,071 |
Net Income to Company | -360.86 | -295.95 | -222.39 | -1,470 | -1,931 | 1,071 |
Minority Interest in Earnings | 108.49 | 187.15 | 17.7 | 908.77 | 1,256 | -1,123 |
Net Income | -252.36 | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 |
Net Income to Common | -252.36 | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 139 | 139 | 139 | 139 | 139 | 139 |
Shares Outstanding (Diluted) | 139 | 139 | 139 | 139 | 139 | 139 |
Shares Change | -0.74% | - | -0.03% | 0.16% | 0.11% | -0.01% |
EPS (Basic) | -1.82 | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 |
EPS (Diluted) | -1.82 | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -483.05 | -30.92 | -18.59 | -541.93 | -1,286 | 375.16 |
Free Cash Flow Per Share | -3.48 | -0.22 | -0.13 | -3.89 | -9.25 | 2.70 |
Gross Margin | 51.80% | 57.19% | 54.91% | 53.32% | 8.28% | 65.05% |
Operating Margin | -19.21% | -9.92% | -15.82% | -106.51% | -157.87% | 19.89% |
Profit Margin | -19.89% | -6.88% | -14.91% | -48.48% | -64.01% | -1.34% |
Free Cash Flow Margin | -38.08% | -1.95% | -1.35% | -46.81% | -121.82% | 9.57% |
EBITDA | -90.42 | -8.95 | -66.3 | -1,078 | -1,498 | 967.36 |
EBITDA Margin | -7.13% | -0.56% | -4.83% | -93.11% | -141.83% | 24.66% |
D&A For EBITDA | 153.26 | 148.05 | 150.9 | 155.15 | 169.35 | 187.4 |
EBIT | -243.68 | -156.99 | -217.2 | -1,233 | -1,667 | 779.96 |
EBIT Margin | -19.21% | -9.92% | -15.82% | -106.51% | -157.87% | 19.89% |
Effective Tax Rate | - | - | - | - | - | 5.78% |